Product Name

Palbociclib

CAS Number

571190-30-2

LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:
Palbociclib
CAS Number:
571190-30-2
Indication:
Palbociclib is indicated as an anticancer treatment to be used in combination with Letrozole for the treatment of metastatic breast cancer. Post-menopausal women who are diagnosed with estrogen receptor positive, human epidermal growth factor receptor 2 negative unresectable breast cancer are candidates for this potent therapy. Palbociclib may be administered as initial endocrine-based treatment. Progression-free survival rates gleaned Palbociclib accelerated approval from the FDA in February 2015.
Mode of Action:

Palbociclib works as a highly potent and selective inhibitor of CDK4 and -6 in patients with advanced estrogen receptor positive, HER-2 negative breast cancer. When used in conjunction with anticancer therapy Letrozole, Palbociclib has proven to significantly promote progression-free survival in patients. Studies have determined that In vitro, Palbociclib reduced cellular proliferation of ER-positive breast cancer cells by effectively blocking the progression of the cell from the G1 into S phase of the cell cycle.

Pharmacodynamics:

Regarding Cardiac Electrophysiology Palbociclib elicited no substantial change in the QTc interval in studies of patients diagnosed with metastatic estrogen receptor positive, HER-2 negative breast cancer. The binding of Palbociclib to plasma proteins in vitro was valued at 85 percent, with no concentration dependence over the expected range of 500 ng/mL to 5000 ng/mL.

Metabolism:

Palbociclib is metabolized both in vitro and in vivo via hepatic metabolism in humans. Post oral administration of a one-time dose of 125 milligrams of Palbociclib the primary metabolic pathways have been observed to involve both oxidation and sulfonation, along with with glucuronidation and acylation as contributing minor pathways.

Toxicity:

The toxicity of Palbociclib alongside Letrozole was found to be acceptable in extensive and comprehensive studies. Adverse events noted included anemia, neutropenia and fatigue.

IUPAC:
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2, 3-d]pyrimidin-7(8H)-one
PubChem:
5330286
Formula:
C24H29N7O2
Molecular Mass:
447.5328
Synonyms:
6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; OTAVA-BB 1115529; PD-0332991; Palbociclib
InChi:
InChI=1/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
General Reference:
General Reference:

Weinberg RA. The Biology of Cancer. 2nd ed. New York: Garland Science; 2014.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128689/

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210. 

Ask us about this product

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants
  • Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any submission type based on specific customer requirements

Find an API Product

Search
Generic filters